Novartis in Society Integrated Report 2023
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
Impact & Health Equity Update 2024
Our 11th annual ESG investor event provided updates on the impact we continue to deliver through inclusive access to innovation, environmental sustainability, and resilient operations, all while ensuring compliance to ESG reporting requirements.
View the event presentation (PDF 1.9 MB)
For more recent progress, we provide a quarterly impact and sustainability update.
Q3 2024 Impact and Sustainability Update (PDF 0.6 MB)
Q2 2024 Impact and Sustainability Update (PDF 0.9 MB)
Q1 2024 Impact and Sustainability Update (PDF 1.4 MB)
Q4 2023 Impact and Sustainability Update (PDF 0.6 MB)
Building trust with society
Building trust with society is a key part of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. Our ESG efforts are integrated across the company and are key to driving long-term sustainable value for our stakeholders.
We believe a focus on our material ESG topics, coupled with our inspired, curious and unbossed culture will drive better performance. ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Reporting and Transparency Hub, which includes the Novartis in Society Integrated Report (PDF 8.4 MB), as well as our other publications.
Access
We are committed to bringing more of our medicines to more people, no matter where they are.
Global Health
We apply our expertise and full organizational capability to address major, unresolved global health challenges.
Ethics, Risk and Compliance
To meet the expectations society has of our industry, we strive to maintain high ethical standards, manage risk effectively and ensure we comply with applicable laws and regulations.
Environmental Sustainability
We understand the link between the health of our planet and the health of our patients. We are making progress in reducing the environmental impact of our operations in line with our near- and long-term targets.
Diversity, Equity & Inclusion
We embrace and champion diversity, equity and inclusion which fuels innovation, drives engagement, and attracts talent.
We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, diversity, equity and inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.
Water project revives rural community in India
Novartis is aiming for water neutrality in our own operations by 2030. In India, we are contributing to this goal through a project near Hyderabad with a nonprofit organization. By tackling both water scarcity and the deprivation it causes, the project has revived the community.
A partnership against epilepsy
Parts of Cameroon have rates of epilepsy that are among the highest in the world. Despite the availability of effective therapies, poverty, a lack of medical resources and superstition about the causes of epilepsy often lead to inadequate treatment and social exclusion for people living with the neurological condition. Novartis is working with a Catholic mission on the ground in a central part of the country to overcome these barriers and improve care.
Materiality Assessment
Our ESG priorities are defined by our materiality assessment, it helps us understand what matters to our stakeholders and how they perceive our impact.
Corporate governance
Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.
Transparent reporting
Transparent reporting has been a central part of our commitment for many years and we continue to make progress in this area.
Reporting and transparency hub
Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures.
Positions on key topics
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.
Awards & recognition
Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our ESG activities.
ESG rating performance
Our performance against environmental, social and governance criteria is reflected in a variety of third-party ratings.
Environmental, Social and Governance (ESG) Index
Novartis aims to report comprehensively and transparently about ESG topics. We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels.